In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection. FMT therapies are not recommended as a treatment for inflammatory bowel diseases (IBD) or irritable bowel syndrome (IBS).
